


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.




溫州康寧醫院

nzhou Kangning Hospital Co., Ltd.

(A joint stock limited liability company incorporated in the People's Republic of China)

Stock code: 2120



References are made to the circular of the first extraordinary general meeting for the year 2023 dated September 8, 2023 (the “Circular”) and the announcements dated September 27, 2023, April 12, 2024 and April 23, 2024 of the Company, in relation to (among others) the deliberation and approval of the Company’s H Share Award and Trust Scheme, the first grant of Award Shares pursuant to the H Share Award and Trust Scheme and grant of Award Shares to connected persons, and the second grant of Award Shares pursuant to the H Share Award and Trust Scheme and grant of Award Shares to connected persons. Capitalized terms used herein shall have the same meanings as those defined in the H Share Award and Trust Scheme set out in Appendix I to the Circular unless the context requires otherwise.

The Company made this announcement in relation to the third grant of Award Shares pursuant to the H Share Award and Trust Scheme on a voluntary basis, to provide Shareholders and potential investors with an update on the latest business development of the Group.

The Board is pleased to announce that on June 18, 2024, pursuant to the H Share Award and Trust Scheme, the Board resolved to make the grant of 335,000 Award Shares to 52 Selected Participants (the “Selected Participants”) (the “Third Grant”) at a grant price of RMB7 per Share, representing approximately 0.45%<sup>(Note)</sup> of the issued share capital of the Company as at the date of this announcement. The Selected Participants of the Third Grant include the mid-level management personnel and technical backbones of the Company. Taking into account the closing price of HK\$11.90 per H Share as stated in the daily quotation sheet issued by the Stock Exchange on June 17, 2024 (being the last trading day prior to the date of this announcement), the 335,000 Award Shares represent the value of HK\$3,986,500. All 335,000 H Shares were purchased by the Trustee through on-market transactions in accordance with the terms of the H Share Award and Trust Scheme. For the avoidance of doubt, the Company will not issue or allot additional new shares in respect of the Third Grant, and accordingly, the Third Grant will not result in any dilution effect on the shareholdings of existing Shareholders of the Company.

*Note: Percentage figures are rounded to two decimal places and calculated on the basis of 74,600,300 issued shares as at the date of this announcement.*

The Company will prepare the Award Letters in accordance with the decision of the Board and/or its authorized persons and enter into the Award Letters with the Selected Participants of the Third Grant, specifying the grant date, the number of Award Shares granted, the vesting conditions and period and the relevant terms and conditions.

The Third Grant is to recognize and reward the hard work and contributions made by the Selected Participants of the Third Grant to the Company, and to provide additional incentives for those Selected Participants of the Third Grant, in order to maintain and further promote the long-term development of the Company. The Third Grant does not have a material impact on the financial position and operating results of the Company. The Third Grant is fair and reasonable and in the interests of the Company and the Shareholders as a whole.

In this announcement, the following expressions have the meanings set out below unless the context requires otherwise:

“Award Shares”	the H Shares certificate granted to a Selected Participant in an Award
“Board”	the board of directors of the Company
“Company”	Wenzhou Kangning Hospital Co., Ltd., a joint stock limited liability company incorporated under the laws of the PRC, the H Shares of which are listed on the Main Board of the Hong Kong Stock Exchange (Stock Code: 2120)
“Director(s)”	the director(s) of the Company
“Group”	the Company and its subsidiaries
“H Shares”	overseas listed foreign shares which are listed on the Stock Exchange, with a nominal value of RMB1.00 each
“H Share Award and Trust Scheme”	the H Share Award and Trust Scheme of the Company
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time

“Selected Participant(s)”	any eligible employee who, in accordance with the H Share Award and Trust Scheme, is approved for participation in the Employee Share Award Scheme and has been granted any corresponding Award under the Scheme
“Stock Exchange”	The Stock Exchange of Hong Kong Limited (香港聯合交易所有限公司)
“Shareholder(s)”	the Shareholder(s) of the Company

By order of the Board

  
 Chairman

Zhejiang, the PRC  
June 18, 2024

*As of the date of this announcement, the Company’s executive Directors are Mr. GUAN Weili, Ms. WANG Lianyue and Mr. WANG Jian; the non-executive Directors are Mr. QIN Hao and Mr. LI Changhao; and the independent non-executive Directors are Ms. ZHONG Wentang, Ms. JIN Ling and Mr. CHAN Sai Keung Hugo.*